November 14, 2025
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential…
Pharmaceuticals, Biotechnology and Life Sciences
– Pre-NDA meeting with FDA to discuss brilaroxazine’s path to approval for schizophrenia planned in Q4 2025 – – Potential…
September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset…
SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology…
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates…
America’s Growth Leaders Cytek Biosciences has been recognized by TIME as one of America’s Growth Leaders of 2026. Presented in…
CARLSBAD, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and…
SUNNYVALE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the…
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period…
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period…
DEER PARK, Ill., Nov. 12, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative…